The Marshall Protocol (MP) is a curative medical treatment for chronic disease, representing the latest molecular evidence. According to the Marshall Pathogenesis, chronic disease is caused by a metagenomic microbiota that persist, in part, by dysregulating vitamin D metabolism.
Physicians worldwide use the MP to treat a variety of chronic inflammatory and autoimmune diseases including but not limited to sarcoidosis, Chronic Fatigue Syndrome, fibromyalgia, Crohn’s Disease, and rheumatoid arthritis. While other treatments for chronic disease use palliative medications in an effort to cover up symptoms, the Marshall Protocol is a curative treatment, which strives to address the root cause of the disease process.
Information about the treatment can be found at this study site and also at autoimmunityresearch.org. The site is run by the staff of the Autoimmunity Research Foundation, a California-based non-profit agency. Over 200 health professionals are members of the site, and discussions are moderated by a group of volunteer nurses. There is no charge to use the website or the treatment and all patients are welcome to participate.
The Marshall Protocol is a phase II community-based Internet study. The FDA has already granted orphan product designations for two of Autoimmunity Research Foundation’s six applications - Sarcoidosis, and Post Treatment Lyme Disease Syndrome PTLDS, commonly known as chronic Lyme.
Publications and Presentations
Papers
Presentations
- Bacteria induced vitamin D receptor dysfunction in autoimmune disease: theoretical and practical implications for interpretation of serum vitamin D metabolite levels
- The Marshall Protocol in a clinical environment – observations from the initial cohort
- The VDR nuclear receptor is key to understanding 'diseases of the aging'
- Understanding human disease requires study of a metagenome, not just the human genome
- VDR receptor competence induces recovery from chronic autoimmune disease
- Vitamin D induced dysregulation of nuclear receptors may account for higher prevalence of some autoimmune diseases in women
- Vitamin D metabolites as clinical markers in autoimmune and chronic illness
